Description

E-Cefprozil is a semi-synthetic, broad-spectrum cephalosporin antibiotic belonging to the second generation of this important pharmaceutical class. Its primary value lies in its enhanced stability against β-lactamases and improved pharmacokinetic profile compared to earlier generations, making it a critical active pharmaceutical ingredient (API). This compound is essential for manufacturers in the pharmaceutical industry developing oral dosage forms to treat a variety of bacterial infections, including those of the respiratory tract, skin, and soft tissues.

Application

E-Cefprozil CAS NO 92676-86-3 serves as the key bioactive component in the formulation of antibiotic medications. Its primary and derived applications include:

• Pharmaceutical API: Core active ingredient in the manufacture of oral antibiotic tablets and capsules.
• Respiratory Infection Treatments: Formulated for medications targeting bronchitis, pneumonia, and pharyngitis.
• Skin and Soft Tissue Infection Medications: Used in antibiotics for treating impetigo, cellulitis, and other dermatological infections.
• Pediatric Suspensions: Incorporated into stable, palatable oral suspension formulations for pediatric use.
• Veterinary Pharmaceutical Development: Potential use in developing antibacterial treatments for veterinary applications.
• Research & Development: Serves as a reference standard and starting material in antimicrobial research and new drug development projects.

Basic Information

Product Name	E-Cefprozil
CAS No.	92676-86-3
Molecular Formula	C18H19N3O5S
Molecular Weight	389.43 g/mol
Synonyms	Cefprozil; (6R,7R)-7-[[(2R)-2-Amino-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-(prop-1-en-1-yl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; BMY-28100; Cefzil; Procef; Cefprozil Anhydrous; Cefprozilum
EINECS	Contact for details

Quality Control

Our E-Cefprozil is manufactured and tested under strict quality management systems. We ensure compliance with major pharmacopoeial standards, including USP (United States Pharmacopeia) and EP (European Pharmacopoeia) monographs where applicable. Every batch undergoes rigorous analytical testing for identity, purity, potency, and specified impurities. A comprehensive Certificate of Analysis (COA) documenting all test results is provided with each shipment to guarantee traceability and batch-to-batch consistency for our global pharmaceutical clients.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). This product is hygroscopic (moisture-sensitive) and must be kept under conditions that minimize exposure to atmospheric humidity to prevent degradation and ensure long-term stability.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time corresponds to reference standard
Assay (HPLC)	98.0% - 102.0% (on anhydrous basis)
Water Content (KF)	≤ 1.0%
Residue on Ignition	≤ 0.2%
Related Substances (HPLC)	Individual impurity: ≤ 0.5% Total impurities: ≤ 2.0%
Heavy Metals	≤ 20 ppm
Microbial Limits	Conforms to EP/USP requirements

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.